Published in J Biol Chem on October 11, 2007
The SUMO pathway: emerging mechanisms that shape specificity, conjugation and recognition. Nat Rev Mol Cell Biol (2010) 4.72
SUMOylation and De-SUMOylation: wrestling with life's processes. J Biol Chem (2008) 3.22
Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med (2012) 3.20
Function and regulation of SUMO proteases. Nat Rev Mol Cell Biol (2012) 2.55
ETV1, 4 and 5: an oncogenic subfamily of ETS transcription factors. Biochim Biophys Acta (2012) 1.58
SUMO Losing Balance: SUMO Proteases Disrupt SUMO Homeostasis to Facilitate Cancer Development and Progression. Genes Cancer (2010) 1.42
SENP1 induces prostatic intraepithelial neoplasia through multiple mechanisms. J Biol Chem (2010) 1.29
Post-translational modifications of nuclear receptors and human disease. Nucl Recept Signal (2012) 1.23
Repression of the SUMO-specific protease Senp1 induces p53-dependent premature senescence in normal human fibroblasts. Aging Cell (2008) 1.09
Induction of SENP1 in endothelial cells contributes to hypoxia-driven VEGF expression and angiogenesis. J Biol Chem (2010) 1.06
Triptolide inhibits the proliferation of prostate cancer cells and down-regulates SUMO-specific protease 1 expression. PLoS One (2012) 1.02
The in vivo role of androgen receptor SUMOylation as revealed by androgen insensitivity syndrome and prostate cancer mutations targeting the proline/glycine residues of synergy control motifs. J Biol Chem (2012) 0.96
Dissecting Major Signaling Pathways throughout the Development of Prostate Cancer. Prostate Cancer (2013) 0.94
Tumor-suppressive microRNA-145 induces growth arrest by targeting SENP1 in human prostate cancer cells. Cancer Sci (2015) 0.88
The prognostic value of SUMO1/Sentrin specific peptidase 1 (SENP1) in prostate cancer is limited to ERG-fusion positive tumors lacking PTEN deletion. BMC Cancer (2015) 0.84
Emerging roles of SUMO modification in arthritis. Gene (2010) 0.84
Transcriptional repression of estrogen receptor α signaling by SENP2 in breast cancer cells. Mol Endocrinol (2013) 0.82
Detection of differentially expressed genes and association with clinicopathological features in laryngeal squamous cell carcinoma. Oncol Lett (2012) 0.82
Pathogenic mechanisms and therapeutic strategies in spinobulbar muscular atrophy. CNS Neurol Disord Drug Targets (2013) 0.80
SUMOylation of HP1α supports association with ncRNA to define responsiveness of breast cancer cells to chemotherapy. Oncotarget (2016) 0.80
SUMO-Specific Protease 2 (SENP2) Is an Important Regulator of Fatty Acid Metabolism in Skeletal Muscle. Diabetes (2015) 0.79
The role of Co²+ in the crystallization of human SENP1 and comments on the limitations of automated refinement protocols. Acta Crystallogr Sect F Struct Biol Cryst Commun (2011) 0.79
Roles of ubiquitination and SUMOylation on prostate cancer: mechanisms and clinical implications. Int J Mol Sci (2015) 0.79
Network analysis of ChIP-Seq data reveals key genes in prostate cancer. Eur J Med Res (2014) 0.78
15-LOX-1 suppression of hypoxia-induced metastatic phenotype and HIF-1α expression in human colon cancer cells. Cancer Med (2014) 0.77
Aberrant sumoylation signaling evoked by reactive oxygen species impairs protective function of Prdx6 by destabilization and repression of its transcription. FEBS J (2014) 0.77
Overview on the complexity of androgen receptor-targeted therapy for prostate cancer. Cancer Cell Int (2015) 0.77
Small ubiquitin-like modifier protein-specific protease 1 and prostate cancer. Asian J Androl (2008) 0.76
SUMO and the robustness of cancer. Nat Rev Cancer (2017) 0.75
SENP1 regulates PTEN stability to dictate prostate cancer development. Oncotarget (2016) 0.75
The Role of the Small Ubiquitin-Related Modifier (SUMO) Pathway in Prostate Cancer. Biomolecules (2012) 0.75
Momordin Ic, a new natural SENP1 inhibitor, inhibits prostate cancer cell proliferation. Oncotarget (2016) 0.75
Chromatin structure analyses identify miRNA promoters. Genes Dev (2008) 5.40
Identification of miRNomes in human liver and hepatocellular carcinoma reveals miR-199a/b-3p as therapeutic target for hepatocellular carcinoma. Cancer Cell (2011) 4.54
SUMO-specific protease 1 is essential for stabilization of HIF1alpha during hypoxia. Cell (2007) 4.46
Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med (2012) 3.20
A tagging-via-substrate technology for detection and proteomics of farnesylated proteins. Proc Natl Acad Sci U S A (2004) 2.74
Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model. Cancer Res (2008) 2.59
SUMO-specific protease 2 is essential for suppression of polycomb group protein-mediated gene silencing during embryonic development. Mol Cell (2010) 2.52
Inflammatory cytokines stimulated C-reactive protein production by human coronary artery smooth muscle cells. Circulation (2003) 2.28
Characterization of a family of nucleolar SUMO-specific proteases with preference for SUMO-2 or SUMO-3. J Biol Chem (2006) 2.15
Role of desumoylation in the development of prostate cancer. Neoplasia (2006) 1.90
SENP1 enhances androgen receptor-dependent transcription through desumoylation of histone deacetylase 1. Mol Cell Biol (2004) 1.89
MicroRNA-99a inhibits hepatocellular carcinoma growth and correlates with prognosis of patients with hepatocellular carcinoma. J Biol Chem (2011) 1.88
Differential regulation of interleukin 1 receptor and Toll-like receptor signaling by MEKK3. Nat Immunol (2003) 1.88
Stimulation of prostate cancer cellular proliferation and invasion by the androgen receptor co-activator ARA70. Am J Pathol (2007) 1.77
Radiation-related heart disease: current knowledge and future prospects. Int J Radiat Oncol Biol Phys (2010) 1.72
A proline-90 residue unique to SUMO-4 prevents maturation and sumoylation. Biochem Biophys Res Commun (2005) 1.68
Release of C-reactive protein in response to inflammatory cytokines by human adipocytes: linking obesity to vascular inflammation. J Am Coll Cardiol (2005) 1.67
Neddylation of a breast cancer-associated protein recruits a class III histone deacetylase that represses NFkappaB-dependent transcription. Nat Cell Biol (2006) 1.62
SUMO1 modification of PTEN regulates tumorigenesis by controlling its association with the plasma membrane. Nat Commun (2012) 1.58
Resistin promotes smooth muscle cell proliferation through activation of extracellular signal-regulated kinase 1/2 and phosphatidylinositol 3-kinase pathways. Circulation (2004) 1.55
Regulation of DNA repair through deSUMOylation and SUMOylation of replication protein A complex. Mol Cell (2010) 1.50
Both cell fusion and transdifferentiation account for the transformation of human peripheral blood CD34-positive cells into cardiomyocytes in vivo. Circulation (2004) 1.46
SUMO Losing Balance: SUMO Proteases Disrupt SUMO Homeostasis to Facilitate Cancer Development and Progression. Genes Cancer (2010) 1.42
SENP3 is responsible for HIF-1 transactivation under mild oxidative stress via p300 de-SUMOylation. EMBO J (2009) 1.41
Heterogeneous expression and functions of androgen receptor co-factors in primary prostate cancer. Am J Pathol (2002) 1.41
Purification and identification of a novel complex which is involved in androgen receptor-dependent transcription. Mol Cell Biol (2003) 1.38
Nucleocytoplasmic shuttling modulates activity and ubiquitination-dependent turnover of SUMO-specific protease 2. Mol Cell Biol (2006) 1.29
SENP1 induces prostatic intraepithelial neoplasia through multiple mechanisms. J Biol Chem (2010) 1.29
Differential regulation of c-Jun-dependent transcription by SUMO-specific proteases. J Biol Chem (2005) 1.28
Emerging paradigms in cardiomyopathies associated with cancer therapies. Circ Res (2013) 1.27
Intra-abdominal adiposity, inflammation, and cardiovascular risk: new insight into global cardiometabolic risk. Curr Hypertens Rep (2008) 1.27
Kaposi's sarcoma-associated herpesvirus K-bZIP represses gene transcription via SUMO modification. J Virol (2005) 1.26
Human CD34+ cells in experimental myocardial infarction: long-term survival, sustained functional improvement, and mechanism of action. Circ Res (2010) 1.26
Vascular complications of selected cancer therapies. Nat Clin Pract Cardiovasc Med (2008) 1.24
Distinct nuclear and cytoplasmic functions of androgen receptor cofactor p44 and association with androgen-independent prostate cancer. Proc Natl Acad Sci U S A (2008) 1.23
Heat shock and Cd2+ exposure regulate PML and Daxx release from ND10 by independent mechanisms that modify the induction of heat-shock proteins 70 and 25 differently. J Cell Sci (2003) 1.20
The androgen receptor directly targets the cellular Fas/FasL-associated death domain protein-like inhibitory protein gene to promote the androgen-independent growth of prostate cancer cells. Mol Endocrinol (2005) 1.19
SENP3-mediated de-conjugation of SUMO2/3 from promyelocytic leukemia is correlated with accelerated cell proliferation under mild oxidative stress. J Biol Chem (2010) 1.16
Regulation of the NEDD8 conjugation system by a splicing variant, NUB1L. J Biol Chem (2003) 1.15
Protein arginine methyltransferase 5 is essential for growth of lung cancer cells. Biochem J (2012) 1.15
Modification of nonstructural protein 1 of influenza A virus by SUMO1. J Virol (2010) 1.13
Disruption of Mekk2 in mice reveals an unexpected role for MEKK2 in modulating T-cell receptor signal transduction. Mol Cell Biol (2002) 1.12
Isocitrate-to-SENP1 signaling amplifies insulin secretion and rescues dysfunctional β cells. J Clin Invest (2015) 1.12
SUMO-specific protease 1 is critical for early lymphoid development through regulation of STAT5 activation. Mol Cell (2012) 1.11
Redox regulation of the stability of the SUMO protease SENP3 via interactions with CHIP and Hsp90. EMBO J (2010) 1.11
NF-κB induction of the SUMO protease SENP2: A negative feedback loop to attenuate cell survival response to genotoxic stress. Mol Cell (2011) 1.09
Fusion of human hematopoietic progenitor cells and murine cardiomyocytes is mediated by alpha 4 beta 1 integrin/vascular cell adhesion molecule-1 interaction. Circ Res (2007) 1.09
Decrease in stromal androgen receptor associates with androgen-independent disease and promotes prostate cancer cell proliferation and invasion. J Cell Mol Med (2008) 1.09
Therapy insight: Management of cardiovascular disease in patients with cancer and cardiac complications of cancer therapy. Nat Clin Pract Oncol (2008) 1.08
Induction of SENP1 in endothelial cells contributes to hypoxia-driven VEGF expression and angiogenesis. J Biol Chem (2010) 1.06
CRP and the risk of atherosclerotic events. Semin Immunopathol (2009) 1.06
Differential expression of SUMO-specific protease 7 variants regulates epithelial-mesenchymal transition. Proc Natl Acad Sci U S A (2012) 1.05
Androgen depletion up-regulates cadherin-11 expression in prostate cancer. J Pathol (2010) 1.04
SUMOylation and de-SUMOylation in response to DNA damage. FEBS Lett (2011) 1.03
Modulation of androgen receptor-dependent transcription by resveratrol and genistein in prostate cancer cells. Prostate (2004) 1.03
Roles of the androgen receptor cofactor p44 in the growth of prostate epithelial cells. J Mol Endocrinol (2006) 1.02
Transcriptional regulation of the TGF-beta1 promoter by androgen receptor. Biochem J (2008) 1.02
Tumor suppressor function of androgen receptor coactivator ARA70alpha in prostate cancer. Am J Pathol (2010) 1.02
Androgen receptor and prostate apoptosis response factor-4 target the c-FLIP gene to determine survival and apoptosis in the prostate gland. J Mol Endocrinol (2006) 1.01
C-reactive protein: structure affects function. Circulation (2004) 1.00
The pleiotropic effects of statins. Curr Opin Cardiol (2005) 0.99
Increased expression of histone deacetylaces (HDACs) and inhibition of prostate cancer growth and invasion by HDAC inhibitor SAHA. Am J Transl Res (2009) 0.99
De-SUMOylation enzyme of sentrin/SUMO-specific protease 2 regulates disturbed flow-induced SUMOylation of ERK5 and p53 that leads to endothelial dysfunction and atherosclerosis. Circ Res (2013) 0.99
Protein arginine methyltransferase 5 functions in opposite ways in the cytoplasm and nucleus of prostate cancer cells. PLoS One (2012) 0.98
The stress response mediator ATF3 represses androgen signaling by binding the androgen receptor. Mol Cell Biol (2012) 0.98
Mitotic regulator Mis18β interacts with and specifies the centromeric assembly of molecular chaperone holliday junction recognition protein (HJURP). J Biol Chem (2014) 0.97
C-reactive protein and atherothrombosis--beyond a biomarker: an actual partaker of lesion formation. Am J Physiol Regul Integr Comp Physiol (2003) 0.95
Identification of a highly conserved domain in the androgen receptor that suppresses the DNA-binding domain-DNA interactions. J Biol Chem (2003) 0.93
Nuclear transport signals control cellular localization and function of androgen receptor cofactor p44/WDR77. PLoS One (2011) 0.92
Sinomenine pretreatment attenuates cold ischemia/reperfusion injury in rats: the role of heme oxygenase-1. Int Immunopharmacol (2010) 0.92
SENP1 deficiency promotes ER stress-induced apoptosis by increasing XBP1 SUMOylation. Cell Cycle (2012) 0.91
The expression and function of androgen receptor coactivator p44 and protein arginine methyltransferase 5 in the developing testis and testicular tumors. J Urol (2007) 0.91
Androgen receptor coactivator p44/Mep50 in breast cancer growth and invasion. J Cell Mol Med (2010) 0.90
The diagnosis and management of cardiovascular disease in cancer patients. Curr Probl Cardiol (2008) 0.89
RNA polymerase III in Cajal bodies and lampbrush chromosomes of the Xenopus oocyte nucleus. Mol Biol Cell (2002) 0.89
A new perspective on the biology of C-reactive protein. Circ Res (2005) 0.87
Adjuvant treatment suppresses IL-17 production by T cell-independent myeloid sources in nonobese diabetic mice. Mol Immunol (2010) 0.87
A novel high-throughput screening system identifies a small molecule repressive for matrix metalloproteinase-9 expression. Mol Pharmacol (2007) 0.87
Altered differentiation and proliferation of prostate epithelium in mice lacking the androgen receptor cofactor p44/WDR77. Endocrinology (2010) 0.87
A novel function of caspase-8 in the regulation of androgen-receptor-driven gene expression. EMBO J (2006) 0.86
Androgen regulation of 5α-reductase isoenzymes in prostate cancer: implications for prostate cancer prevention. PLoS One (2011) 0.86
Molecular imaging of mesenchymal stem cell: mechanistic insight into cardiac repair after experimental myocardial infarction. Circ Cardiovasc Imaging (2011) 0.86
The activity-dependent stimuli increase SUMO modification in SHSY5Y cells. Biochem Biophys Res Commun (2009) 0.85
Hepatoprotective action of Radix Paeoniae Rubra aqueous extract against CCl4-induced hepatic damage. Molecules (2011) 0.85
Inhibition of tumor-necrosis-factor-alpha induced endothelial cell activation by a new class of PPAR-gamma agonists. An in vitro study showing receptor-independent effects. J Vasc Res (2005) 0.84
PROCLAIM: pilot study to examine the effects of clopidogrel on inflammatory markers in patients with metabolic syndrome receiving low-dose aspirin. Tex Heart Inst J (2009) 0.84
Dual targeting of tumor angiogenesis and chemotherapy by endostatin-cytosine deaminase-uracil phosphoribosyltransferase. Mol Cancer Ther (2011) 0.84
Negative androgen-response elements mediate androgen-dependent transcriptional inhibition of TGF-β1 and CDK2 promoters in the prostate gland. J Androl (2011) 0.83
SUMO-specific protease 1 regulates mitochondrial biogenesis through PGC-1α. J Biol Chem (2012) 0.83
Disturbed flow-activated p90RSK kinase accelerates atherosclerosis by inhibiting SENP2 function. J Clin Invest (2015) 0.83
Role of SUMO-specific protease 2 in reprogramming cellular glucose metabolism. PLoS One (2013) 0.82